(AMN) AMN Healthcare - Ratings and Ratios
Nurse Staffing, Physician Staffing, Technology
AMN EPS (Earnings per Share)
AMN Revenue
Description: AMN AMN Healthcare
AMN Healthcare Services, Inc. is a leading provider of technology-enabled healthcare workforce solutions and staffing services in the United States, catering to acute and sub-acute care hospitals, and other healthcare facilities. The companys comprehensive suite of services is delivered through three primary segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions.
The Nurse and Allied Solutions segment is a major contributor, offering a range of staffing services including travel nurse staffing, local staffing, and allied staffing, as well as permanent placement solutions for international nurses and allied health professionals. Additionally, this segment provides specialized services such as crisis nurse staffing and teletherapy platforms, addressing the diverse needs of healthcare facilities, schools, and other organizations.
The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions, while the Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions, further enhancing the companys capabilities.
AMN Healthcare Services operates under multiple brands, including AMN Healthcare, Nursefinders, and OGrady Peyton International, among others, allowing the company to maintain a strong presence in the market. With its founding in 1985 and headquarters in Dallas, Texas, the company has established itself as a key player in the healthcare staffing industry.
From a technical analysis perspective, AMNs stock has shown a recent price of $21.91, with its 20-day SMA at $21.30 and 50-day SMA at $20.68, indicating a potential upward trend. However, the 200-day SMA stands at $28.25, suggesting a longer-term downtrend. The ATR of 0.92 represents a 4.21% daily volatility, and the stocks 52-week high and low are $68.05 and $17.79, respectively.
Fundamentally, AMN Healthcare Services has a market capitalization of $853.79M USD and a forward P/E ratio of 24.75, indicating a relatively high valuation. The companys return on equity is currently negative at -20.74, which may raise concerns about its profitability.
Forecast: Based on the technical and fundamental data, a potential forecast for AMN Healthcare Services could be a short-term price increase, driven by the recent upward trend and the stocks proximity to its 20-day and 50-day SMAs. However, the long-term downtrend indicated by the 200-day SMA and the negative RoE may pose a risk to the stocks sustainability. As such, a cautious approach may be warranted, with a potential entry point around $20.50-$21.00, and a stop-loss below $20.00. A reversion to its 52-week high is unlikely in the short term, and the stock may continue to consolidate around its current price levels.
AMN Stock Overview
| Market Cap in USD | 760m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2001-11-13 |
AMN Stock Ratings
| Growth Rating | -84.9% |
| Fundamental | 28.2% |
| Dividend Rating | 2.89% |
| Return 12m vs S&P 500 | -65.5% |
| Analyst Rating | 3.33 of 5 |
AMN Dividends
Currently no dividends paidAMN Growth Ratios
| Growth Correlation 3m | -47.4% |
| Growth Correlation 12m | -88% |
| Growth Correlation 5y | -63.9% |
| CAGR 5y | -43.32% |
| CAGR/Max DD 3y | -0.50 |
| CAGR/Mean DD 3y | -0.83 |
| Sharpe Ratio 12m | -1.54 |
| Alpha | 0.14 |
| Beta | 0.803 |
| Volatility | 46.63% |
| Current Volume | 728.1k |
| Average Volume 20d | 923.5k |
| Stop Loss | 18 (-6.5%) |
| Signal | 0.43 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-297.8m TTM) > 0 and > 6% of Revenue (6% = 166.2m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 4.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.08% (prev 4.05%; Δ -4.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 310.7m > Net Income -297.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.4m) change vs 12m ago 0.47% (target <= -2.0% for YES) |
| Gross Margin 29.84% (prev 28.16%; Δ 1.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 111.2% (prev 116.7%; Δ -5.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.25 (EBITDA TTM -157.4m / Interest Expense TTM 61.2m) >= 6 (WARN >= 3) |
Altman Z'' 1.65
| (A) -0.00 = (Total Current Assets 571.4m - Total Current Liabilities 573.6m) / Total Assets 2.21b |
| (B) 0.54 = Retained Earnings (Balance) 1.19b / Total Assets 2.21b |
| (C) -0.13 = EBIT TTM -321.7m / Avg Total Assets 2.49b |
| (D) 0.74 = Book Value of Equity 1.19b / Total Liabilities 1.60b |
| Total Rating: 1.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.19
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 15.50% = 5.0 |
| 3. FCF Margin 9.22% = 2.31 |
| 4. Debt/Equity 1.53 = 1.43 |
| 5. Debt/Ebitda -5.90 = -2.50 |
| 6. ROIC - WACC (= -22.90)% = -12.50 |
| 7. RoE -40.80% = -2.50 |
| 8. Rev. Trend -96.24% = -7.22 |
| 9. EPS Trend -96.64% = -4.83 |
What is the price of AMN shares?
Over the past week, the price has changed by +1.58%, over one month by -0.87%, over three months by -13.83% and over the past year by -58.84%.
Is AMN Healthcare a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMN is around 12.10 USD . This means that AMN is currently overvalued and has a potential downside of -37.18%.
Is AMN a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the AMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.3 | 5.3% |
| Analysts Target Price | 20.3 | 5.3% |
| ValueRay Target Price | 13 | -32.4% |
Last update: 2025-09-05 04:32
AMN Fundamental Data Overview
CCE Cash And Equivalents = 41.5m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 18.5529
P/S = 0.2745
P/B = 1.2514
P/EG = 1.7113
Beta = 0.102
Revenue TTM = 2.77b USD
EBIT TTM = -321.7m USD
EBITDA TTM = -157.4m USD
Long Term Debt = 916.5m USD (from longTermDebt, last quarter)
Short Term Debt = 12.6m USD (from shortTermDebt, last quarter)
Debt = 929.0m USD (Calculated: Short Term 12.6m + Long Term 916.5m)
Net Debt = 805.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.65b USD (760.4m + Debt 929.0m - CCE 41.5m)
Interest Coverage Ratio = -5.25 (Ebit TTM -321.7m / Interest Expense TTM 61.2m)
FCF Yield = 15.50% (FCF TTM 255.5m / Enterprise Value 1.65b)
FCF Margin = 9.22% (FCF TTM 255.5m / Revenue TTM 2.77b)
Net Margin = -10.75% (Net Income TTM -297.8m / Revenue TTM 2.77b)
Gross Margin = 29.84% ((Revenue TTM 2.77b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Tobins Q-Ratio = 1.39 (Enterprise Value 1.65b / Book Value Of Equity 1.19b)
Interest Expense / Debt = 1.22% (Interest Expense 11.4m / Debt 929.0m)
Taxrate = 21.0% (US default)
NOPAT = -321.7m (EBIT -321.7m, no tax applied on loss)
Current Ratio = 1.00 (Total Current Assets 571.4m / Total Current Liabilities 573.6m)
Debt / Equity = 1.53 (Debt 929.0m / last Quarter total Stockholder Equity 607.6m)
Debt / EBITDA = -5.90 (Net Debt 805.0m / EBITDA -157.4m)
Debt / FCF = 3.64 (Debt 929.0m / FCF TTM 255.5m)
Total Stockholder Equity = 730.0m (last 4 quarters mean)
RoA = -13.46% (Net Income -297.8m, Total Assets 2.21b )
RoE = -40.80% (Net Income TTM -297.8m / Total Stockholder Equity 730.0m)
RoCE = -19.54% (Ebit -321.7m / (Equity 730.0m + L.T.Debt 916.5m))
RoIC = -18.33% (NOPAT -321.7m / Invested Capital 1.75b)
WACC = 4.57% (E(760.4m)/V(1.69b) * Re(8.98%)) + (D(929.0m)/V(1.69b) * Rd(1.22%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -36.36 | Cagr: -1.23%
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 72.43% ; FCFE base≈235.3m ; Y1≈204.2m ; Y5≈163.1m
Fair Price DCF = 65.85 (DCF Value 2.52b / Shares Outstanding 38.3m; 5y FCF grow -16.15% → 3.0% )
EPS Correlation: -96.64 | EPS CAGR: -54.21% | SUE: 0.93 | # QB: 3
Revenue Correlation: -96.24 | Revenue CAGR: -18.07% | SUE: 0.77 | # QB: 0
Additional Sources for AMN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle